Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21 2024 - 7:00AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that management will
present at and participate in the following conferences in
March.
- The TD Cowen 44th Annual Healthcare Conference in Boston, MA
- Panel Discussion: Orphan Epilepsies - March 6 at 10:30 a.m.
E.T.
- Leerink Partners 2024 Global Biopharma Conference in Miami, FL
- Presentation - March 11 at 4:00 p.m. E.T.
Links to the events can be accessed on the Investors and Media
page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations. A replay of the
webcast will be available approximately two hours after the
completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company first introduced FDA-approved prescription
medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in
2022 and continues to invest in the potential of ganaxolone in IV
and oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221704060/en/
Investors Jim DeNike Senior
Director, Investor Relations Marinus Pharmaceuticals, Inc.
jdenike@marinuspharma.com Media
Molly Cameron Director, Corporate Communications & Investor
Relations Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024